A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. In a context of fungi showing increasing drug resistance, these findings may be useful in both medical and agricultural applications.
The research project, led by prof. Patrick Van Dijck, is rooted in the growing problem of antifungal drug resistance. Candida cells, for example, are quickly becoming tolerant to fluconazole, the most-used antifungal drug. Next to exploring experimental new techniques, scientists also seek to repurpose existing substances. Plant essential oils (EOs), metabolites obtained by steam distillation or cold citrus peel pressing, may offer interesting opportunities: they are made up of compounds that help protect the plant against microbial or herbivore attacks.
Identifying EOs and their compounds
In the VIB-KU Leuven Center for Microbiology, Adam Feyaerts gathered a collection of 175 different EOs, constituting a collection of over one thousand different small molecules. The aim was to identify biologically active compounds present in these complex mixtures. They therefore developed a new class of assay that allowed to identify new volatile substances with antifungal activities over a distance.
Prof. Patrick Van Dijck (VIB-KU Leuven): “We screened our whole collection of EOs for vapor-phase mediated antifungal activity against two human fungal pathogens, Candida albicans and Candida glabrata. Interestingly, we found that approximately half of the EOs and their compounds had vapour-phase-mediated activity against bothCandida species. Surprisingly, C. glabrata, the most drug-resistant species of the two was on average even more susceptible. In contrast, none of the currently used antifungals showed any vapour-phase-mediated activity.”
Numerous potential applications
This is now the first simple test to look for the vapor-phase-mediated antimicrobial activity of molecules. The same assay could also be used to test other biological activity. And although these findings still have to be confirmed in clinical trials, potential applications are numerous.
Co-author Adam Feyaerts (VIB-KU Leuven): “Our findings are for instance a starting point for the development of molecules that could also be used in vaporizers. After all, volatiles can access otherwise hard to reach areas. Think of possibilities such as maintaining hygiene in hospitals or treat patients with lung infections. There are agricultural options too, such as preventing post-harvest contamination or protecting crops against pests.”
The Latest on: Antifungal drug resistance
Deep-sea marine sponges may hold key to antibiotic drug resistance
on June 19, 2018 at 7:52 am
Credit: FAU's Harbor Branch Oceanographic Institute Drug resistance to antibiotics is on the rise and ... Among them, several strains were identified for their potent antifungal activity, for anti-MRSA activity, and for both antifungal and antibacterial ... […]
FDA mulls new incentives to stem antimicrobial resistance
on June 13, 2018 at 8:47 am
Antimicrobial resistance is today one of the biggest public health ... The Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway), part of the 21st Century Cures Act, could help to advance development and approval of antibacterial ... […]
FDA Issues Draft Guidance to Aid Development of Critical Drugs
on June 13, 2018 at 1:08 am
He noted that, as resistant strains of bacteria increase ... and his statement discusses a set of incentives created by Congress for antibacterial and antifungal drugs that treat serious or life-threatening infections. This includes the qualified ... […]
FDA considers changing reimbursement model for new antimicrobial drugs
on June 12, 2018 at 1:02 pm
The FDA is discussing changing the reimbursement model for certain new antimicrobial drugs that target multidrug-resistant infections ... the Limited Population Pathway for Antibacterial and Antifungal Drugs, (LPAD) pathway, which was established by ... […]
Integrated BioSci Research On Cidara Therapeutics: What's In Store For This Promising Antibiotic Innovator?
on June 8, 2018 at 2:43 am
Accordingly, Cidara is brewing a novel next-generation echinocandin, an antifungal known as rezafungin ... platform that utilizes antibody-drug conjugates (“ADC”) for the treatment of multi-drug resistant (“MDR”) gram-negative bacterial infections. […]
Antifungal drug kills dormant colorectal cancer cells
on June 3, 2018 at 12:04 am
Though various treatments are available for it, certain tumor cells are therapy-resistant. Now, research suggests that an antifungal drug may be effective against these persistent cells. But researchers from the Cancer Research UK Cambridge Institute have ... […]
What is antimicrobial resistance?
on May 25, 2018 at 5:00 pm
Antimicrobial resistance is the broader term for resistance in different types of microorganisms and encompasses resistance to antibacterial, antiviral, antiparasitic and antifungal drugs. Antimicrobial resistance occurs naturally but is facilitated by the ... […]
via Google News and Bing News